Physician profile
Hamid Raza
NPI 1437788460
$1,613.08
in general payments reported to CMS, 2019-2025
22 companies · $813 in 2025
The $813 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.96 · 2023: $126 · 2024: $611 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143 · Education: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.67 |
| Education | $407.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $299.93 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $240.90 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Lilly USA, LLC | $164.78 | 2024-2025 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $152.76 | 2024-2025 | Ninlaro, Iclusig, Alunbrig |
| Boston Scientific Corporation | $98.85 | 2023 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $86.83 | 2022-2025 | |
| Genentech USA, INC. | $84.44 | 2024-2025 | Polivy, Itovebi, Venclexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.53 | 2024-2025 | |
| Pfizer INC. | $50.32 | 2024-2025 | |
| Daiichi Sankyo INC. | $46.68 | 2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $39.50 | 2025 | |
| Servier Pharmaceuticals LLC | $34.86 | 2025 | |
| Amneal Pharmaceuticals LLC | $28.42 | 2024 | Neulasta, Avastin, Neupogen |
| Stemline Therapeutics INC. | $27.34 | 2025 | Orserdu |
| Glaxosmithkline, LLC. | $26.65 | 2023 | Trelegy Ellipta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $25.74 | 2025 | Cabometyx |
| Eisai INC. | $24.50 | 2024 | |
| Caris Mpi, INC. | $22.99 | 2025 | Mi Cancer Seek |
| Alexion Pharmaceuticals, INC. | $21.92 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $20.05 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.63 | 2025 | |
| Genzyme Corporation | $17.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.